Plenary Perspectives Special Section.
Keep an eye on emerging molecular and behavioral targets for Fragile X and Angelman syndromes that may inform future ABA treatment planning.
01Research in Context
What this study did
Symons (2022) wrote a plenary summary. It pulls together three short papers on Fragile X, Angelman, and early language disorders.
The goal was to map where science is heading. No new data were collected.
What they found
The review flags new molecular and behavioral targets. These may shape future ABA programs.
No treatment outcomes are reported. The paper is a signpost, not a result.
How this fits with other research
Ferreri et al. (2011) already showed ABA can cut problem behavior in Fragile X. Frank’s 2022 call for “molecular and behavioral targets” lines up with that work and asks for more precision.
Duis (2022) gives a deep dive on Angelman gene therapy. Frank’s short note on Angelman fits inside that bigger landscape.
Scott et al. (2026) found only half of Fragile X babies get early-intervention services by age 1. Frank’s push for new targets lands in a system with clear access gaps.
Why it matters
BCBAs can start prepping for combo care. Track the new drug trials and build behavior probes that match the molecular endpoints. When a family asks about upcoming treatments you will have data-ready baselines to share with the medical team.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Add a line to your intake form asking if the child is enrolled in any gene-therapy or drug trial so you can align behavior data with medical endpoints.
02At a glance
03Original abstract
The following special section represents a still relatively new AJIDD initiative in which we feature short scientific perspectives based on invited plenary talks at national conferences with high relevance for intellectual and developmental disabilities (IDD) research. This Plenary Perspectives Special Section reflects the theme of the 2021 Gatlinburg Conference on Research and Theory in Intellectual and Developmental Disabilities, which, due the COVID pandemic, was held virtually on April 5–8, 2021, and featured the theme of Interventions and Clinical Treatments for Intellectual Disabilities, organized by the Lifespan Institute at the University of Kansas along with the Baylor College of Medicine. Three invited plenary speakers addressed advances at the frontiers of our basic scientific knowledge and clinical understanding of treatment target development and treatment trials for Fragile X syndrome, Angelman syndrome, and early language and communication disorders. Each speaker was asked to summarize their talk as a general "Scientific Perspectives" short paper focusing on background issues, contemporary advances, and future outlook. The Gatlinburg Conference, established in the 1960s and supported, in part, by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), has a long and rich tradition in psychological theory, and social, behavioral, and bio-behavioral research in IDD with an important commitment to supporting pre- and post-doctoral trainees as the next generation of leaders in the IDD field.
American journal on intellectual and developmental disabilities, 2022 · doi:10.1352/1944-7558-127.2.89